PC-027 · nootropic · pe-22-28
PE-22-28
Spadin analogue
Also: Anti-TREK-1
§ Overview
A heptapeptide derived from the Sortilin protein that acts as an antagonist of the TREK-1 potassium channel. PE-22-28 has shown rapid-onset antidepressant-like effects in animal studies, working within 4 days compared to weeks for SSRIs. It represents a novel mechanism for treating depression.
§ Mechanism
Blocks TREK-1 (TWIK-related potassium channel-1), a two-pore domain potassium channel implicated in depression. TREK-1 knockout mice are resistant to depression. Blocking this channel enhances serotonergic neurotransmission and promotes neurogenesis in the hippocampus.
§ Common Uses
- → Antidepressant
- → Mood enhancement
- → Cognitive function
- → Neurogenesis
§ Reported Side Effects
- · Unknown (no human trials)
- · Mild headache (anecdotal)
§ Research, Experiences & Trends
Mechanism of Action
Blocks TREK-1 (TWIK-related potassium channel-1), a two-pore domain potassium channel implicated in depression. TREK-1 knockout mice are resistant to depression. Blocking this channel enhances serotonergic neurotransmission and promotes neurogenesis in the hippocampus.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Unknown (no human trials)
- • Mild headache (anecdotal)